SillaJen said it will absorb Woosung Pharmaceutical, finalizing a full merger in the third quarter of 2025 following board approval. The decision was made through a board resolution passed the same day, after acquiring Woosung Pharmaceutical in March this year.
The merger process is expected to be completed within the second quarter, pending the signing of a formal merger agreement and final board approvals from both parties. SillaJen said it plans to incorporate Woosung Pharmaceutical as a core business unit after the merger.
Woosung Pharmaceutical specializes in intravenous (IV) formulations and supplies large general hospitals, including tertiary care institutions.
Its leading products include Propine Fusion and New Aminophen Premix—acetaminophen-based IV drugs with strong market share. Propine Fusion is also indicated for pediatric use, providing a key competitive advantage. The company’s portfolio additionally includes antivirals, essential minerals, and ibuprofen injections.
One of its pipeline products—a dexibuprofen IV formulation supported by a government R&D program—is expected to become the world’s first of its kind. SillaJen anticipates it could be launched as an improved drug within three years.
SillaJen, historically focused on clinical research in major hospitals, expects to generate synergy by combining its research capabilities and infrastructure with Woosung Pharmaceutical’s commercial operations. The company noted that the merger will significantly improve its revenue, helping it meet the minimum sales requirements to maintain its listing status.
“With this transaction, SillaJen aims to secure both business rationale and long-term value as a biopharmaceutical company by fulfilling revenue criteria through our core pharmaceutical business,” a company official said. “Since this is a small-scale merger, we expect the process to be finalized without complications within the second quarter.”
The company will provide full support for Woosung Pharmaceutical’s future product pipeline and sales growth, he added.